With this Postgraduate diploma, you will learn the leading strategies for accessing the market of new drugs in the pharmaceutical industry"

The Access Market department plays a crucial role in the biopharmaceutical industry, being responsible for managing the entire development and commercialization process of a new product. In this line, the professionals who practice in this area are responsible for ensuring compliance with the requirements of public administrations to incorporate innovative drugs into the market. In this way, the specialist who wishes to be part of this sector is obliged to keep up to date with the procedures required to make these drugs available to the client.

For this reason, TECH has created this degree, through which the student will delve into the most avant-garde intricacies of the Market Access in Pharma Biotech. Throughout this academic period, students will delve into the recent processes of authorization and registration of new drugs or learn about the structure of organizations focused on evaluating these drugs. In addition, you will identify cutting-edge strategies to ensure optimal integration of a biopharmaceutical product in the market.

This academic proposal is presented in a 100% online format, which enables students to complete their studies from any device with an internet connection, adapting to their own personal and professional needs. Likewise, you will enjoy teaching through the Relearning method, which allows you to understand complex concepts more efficiently in less time.

Learn about the importance of the Access Market department for the development of biopharmaceutical products"

This Postgraduate diploma in Market Access in Pharma Biotech contains the most complete and up-to-date scientific program on the market. The most important features include:

• The development of practical cases presented by experts in Pharma Biotech
• The graphic, schematic, and practical content with which they are created, provide scientific and practical information on the disciplines that are essential for professional practice
• Practical exercises where self-assessment can be used to improve learning
• Its special emphasis on innovative methodologies
• Theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Content that is accessible from any fixed or portable device with an Internet connectio

You will delve into the key functions of the market access department and become the most up-to-date expert in the pharmaceutical and biotech environment"

The program's teaching staff includes professionals from the sector who contribute their work experience to this program, in addition to renowned specialists from leading societies and prestigious universities.

Its multimedia content, developed with the latest educational technology, will provide the professional with situated and contextual learning, i.e., a simulated environment that will provide an immersive education programmed to learn in real situations.

The design of this program focuses on Problem-Based Learning, by means of which the professional must try to solve the different professional practice situations that are presented throughout the academic course. For this purpose, the student will be assisted by an innovative interactive video system created by renowned experts.

TECH Relearning method allows you to delve deeper into the key aspects of the syllabus at your own pace of study to consolidate your knowledge"

Update yourself 100% online without giving up your professional and personal life"

The content that is part of this Postgraduate diploma in Market Access in Pharma Biotech covers relevant topics in this field, delving into the updated phases to achieve a successful entry of a new drug in the market. Furthermore, the Relearning method of this degree will allow students to acquire the key concepts of the syllabus at their own pace of study and using less time than with other academic methodologies.

Choose the multimedia didactic formats that best suit your study needs and optimize your updating"

Module 1. Market access (1). Organization and Processes

1.1. Market Access in the pharmaceutical industry

1.1.1. What do we mean by Market Access?
1.1.2. Why is a Market Access department necessary?
1.1.3. Functions of the Market Access department
1.1.4. Conclusions
1.1.5. National Health System (NHS). Organization, Structure and Functions
1.1.6. Health care expenses and drug expenses
1.1.7. Regional Health Service
1.1.8. Organization, Structure and Functions

1.2. Authorization and registration of new drugs

1.2.1. Health Authorities
1.2.2. European Medicines Agency (EMA)
1.2.3. Ministry of Health
1.2.4. New drug marketing authorization process: centralized, decentralized and mutual recognition processes.

1.3. Evaluation of new drugs at national level

1.3.1. Health Technology Assessment Agencies.
1.3.2. Relations
1.3.3. Europe
1.3.4. Therapeutic Positioning Reports(TPR)
1.3.5. Decision makers and influencers

1.4. Other new drug evaluations

1.4.1. GENESIS group evaluations
1.4.2. Regional evaluations
1.4.3. Evaluations in hospital pharmacies: Pharmacy and Therapeutics Committees.
1.4.4. Other evaluations

1.5. From drug approval to availability to the patient

1.5.1.  New drug pricing and reimbursement application process
1.5.2. Marketing and financing conditions
1.5.3. Procedure for access to medicines at hospital level
1.5.4. Access procedure for drugs dispensed in street pharmacies.
1.5.5. Access to generic and biosimilar drugs.

1.6. Drug Financing

1.6.1. Traditional versus new financing schemes
1.6.2. Innovative agreements
1.6.3. Risk-sharing agreements (RSAs)
1.6.4. Types of ARC
1.6.5. Criteria for ARC selection

1.7. Medication Purchasing Process

1.7.1. Public contracting
1.7.2. Centralized Purchasing of Medicines and Medical Devices
1.7.3. Framework agreements
1.7.4. Conclusions

1.8. Market Access Department (1). Professional Profiles

1.8.1. Evolution of the Market Access professional profile
1.9.2. Professional profiles in Market Access
1.8.3. Market Access Manager
1.8.4. Pharmaco-economics
1.8.5. Pricing
1.8.6. Key Account Manager

1.9. Market Access Department (2). Interaction with other departments of the pharmaceutical industry.

1.9.1. Marketing and Sales
1.9.2. Medical Department
1.9.3. Institutional Relations 
1.9.4. Regulatory
1.9.5    Communication

Module 2. Market access (2). Tools and Strategy

2.1. Market access planning for a drug

2.1.1. Analysis of the current scenario: management of the disease, competitors
2.1.2. Region and account segmentation
2.1.3. Scientific Societies
2.1.4. Patient Associations
2.1.5. Designing the Corporate Strategy:
2.1.6. Strategy implementation chronology

2.2. Market access Management for a drug

2.2.1. Access Management at Regional Level
2.2.2. Access to the hospital drug market. Hospital pharmacy management and strategy
2.2.3. Access to the street pharmacy drug market.
2.2.4. Primary care pharmacist management and strategy

2.3. Clinical value of a drug

2.3.1. Value based on clinical development
2.3.2. Real Life Studies
2.3.3. (RWD/RWE)
2.3.4. Conclusions

2.4. Value perceived by the patient

2.4.1.  Patient Reported Outcomes, PRO)
2.4.2. Quality of Life Related to Health(CVRS)
2.4.3. Treatment  Satisfaction
2.4.4. Incorporation of patient preferences

2.5. Economic analysis. Types

2.5.1. Types of Economic Analysis
2.5.2. Parameters to be defined
2.5.3. Partial economic assessments
2.5.4. Costs and Burden of the the Disease
2.5.5. Cost consequence

2.6. Studies of Economic Analysis

2.6.1. Budget Impact Studies
2.6.2. Market growth
2.6.3. Associated risks
2.6.4. Intellectual Property

2.7. Assessments of Economic Analysis

2.7.1. Full economic assessments
2.7.2. Cost-Effectiveness Analysis
2.7.3. Cost-Utility Analysis
2.7.4. Cost-Benefit Analysis
2.7.5. Decision Rules

2.8. Drug value dossier

2.8.1. Contents of the value dossier
2.8.2. The clinical value of the drug
2.8.3. The economic value of the drug
2.8.4. Demonstrating the value of the drug to the health care system
2.8.5. Adaptation of the dossier to the different Autonomous Communities.

2.9. Documents required for the price and reimbursement request

2.9.1. Documentation Requirements
2.9.2. Optional Documents
2.9.3. Price documents
2.9.4. Reimbursement documents

2.10. New Trends

2.10.1. Value-based purchasing
2.10.2. Multicriteria Analysis (MCA)
2.10.3. Innovative Public Procurement
2.10.4. Latest Trends

Module 3. Digital Health Management: Technological Innovation in the Health Sector

3.1. Hospital information systems

3.1.1. Implementation
3.1.2. Management of Hospital information systems
3.1.3. Electronic Medical Records
3.1.4. Information Systems Interoperability

3.2. Telemedicine and digital health

3.2.1. Remote medical consultations
3.2.2. Tele-monitoring platforms
3.2.3. Patient Monitoring
3.2.4. Mobile health and wellness applications

3.3. Big data and data analysis in healthcare

3.3.1. Management and Analysis of Large Volumes of Data in health
3.3.2. Use of predictive analysis  for Decision-Making
3.3.3. Privacy
3.3.4. Health data security

3.4. Artificial intelligence and machine learning in healthcare

3.4.1. Artificial intelligence applications in medical diagnostics
3.4.2. Machine learning algorithms for pattern detection
3.4.3. Chatbots
3.4.4. Virtual assistants in medical care

3.5. The Internet of Things (IoT) in health

3.5.1. Connected medical devices and remote monitoring
3.5.2. Intelligent hospital infrastructures
3.5.3. IoT applications in inventory management
3.5.4. Supplies

3.6. Cybersecurity in healthcare

3.6.1. Health data protection and regulatory compliance
3.6.2. Prevention of cyber attacks
3.6.3. Ransomware
3.6.4. Security audits and incident management

3.7. Virtual Reality (RV) and Augmented Reality(RA) in Medicine

3.7.1. Medical training using VR simulators
3.7.2. AR applications in assisted surgery
3.7.3. Surgical guides
3.7.4. VR therapy and rehabilitation

3.8. Robotics in medicine

3.8.1. Use of surgical robots in medical procedures
3.8.2. Automation of tasks in hospitals and laboratories
3.8.3. Prosthesis
3.8.4. Robotic assistance in rehabilitation

3.9. Medical Images Analysis

3.9.1. Medical image processing and computational analysis
3.9.2. Computer-aided image diagnosis
3.9.3. Real-time medical imaging
3.9.4. 3D

3.10. Blockchain in healthcare

3.10.1. Security and traceability of health data with blockchain
3.10.2. Exchange of medical information between institutions
3.10.3. Management of Informed Consent
3.10.4. Privacy

Don't miss the opportunity to take this course and make a difference in the pharmaceutical and biotechnology industry"